Teva Pharmaceutical Industries
About Teva Pharmaceutical Industries
Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com. Please note that adverse effects for any of our products should be reported to: Safety. AE@teva.co.il Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here:
Recent News
Pharmaceutical Executive Daily: Rocket Pharmaceuticals Sells Pediatric Disease Priority Review Voucher
Analysts See 11% Upside for Teva Despite 100% Rally
Pharma and Biotech M&As 2026 Deal Watcher
Teva's AUSTEDO Shows Quality‑of‑Life Gains in Huntington's Chorea Study
Teva Launches “Home Ground” Online Resource for People Living with Schizophrenia and Their Care Partners
Blackstone Life Sciences Puts $400 Million Behind Teva’s Autoimmune Drug Duvakitug
Teva Shows Positive Real‑World Evidence for AUSTEDO & AUSTEDO XR in Huntington’s Chorea
Federal Circuit Reverses JMOL and Reinstates Jury Verdict in Teva V. Lilly
Patentee Secures Reversal of JMOL on Written Description and Enablement for Method of Treatment by Administering Genus of Antibodies at Federal Circuit
Pharmaceutical Patent Written Description and Enablement Headaches? The Federal Circuit Clarifies a Cure
Former Ovid CEO Dr. Jeremy Levin’s Rallying Cry for Biotech
Shilpa Medicare Appoints Dr. Vellaian Karuppiah as COO to Drive Operational Growth
Teva Intensifies Biosimilar Competition with FDA Approval and Dual Filing Acceptance in US and Europe
Teva's $40 Target: Olanzapine, Specialty Drugs and Biosimilars Fuel Upside
STAT+: Biotech Veteran Jeremy Levin on Why the Industry’s Future Is Secure, but American Leadership Is at Risk
Top Biotech Deals in April 2026
Marquis Who's Who Honors Michael Spanbauer and Elbert Sanders in HR
Teva V. Lilly: Conflicting Positions at PTAB and District Court Sink Patent Challenge
Alvotech Resubmits FDA BLAs for Simponi and Eylea Biosimilars Amid Reykjavik Facility Remediation
Focus on Biosimilar Adoption: Driving Uptake Through Strategy
Teva's AUSTEDO Shows Quality‑of‑Life Gains in Huntington’s Disease Chorea Study
Teva Launches Ahzantive Aflibercept Biosimilar for Retinal Diseases in Europe
Viatris Recalls Extended-Release Xanax over Dissolution Test Failure